Risk Factors Associated with Mortality in Nosocomial Stenotrophomonas maltophilia Pneumonia: A Single-Center Retrospective Study
Abstract
Background: Stenotrophomonas maltophilia (S. maltophilia) is a multidrug-resistant pathogen frequently isolated in hospital-acquired pneumonia and represents a significant clinical challenge. This study aimed to investigate the risk factors associated with 30-day mortality in patients diagnosed with S. maltophilia pneumonia.
Methods: This retrospective, single-center study included patients aged 18 years and older who were hospitalized between January 2018 and December 2021, had S. maltophilia isolated from respiratory samples, and demonstrated clinical and radiological evidence of pneumonia. Patients were grouped by 30-day survival status, and comparisons were made for demographic characteristics, risk factors, and antibiotic regimens.
Results: Among the 200 evaluated patients, colonization was detected in 48%. A total of 104 patients met the inclusion criteria, of whom 75% required ICU admission. The 30-day mortality rate was 55.7%. Malignancies were present in 62.5%. Polymicrobial infections and coinfections were observed in 39.4% and 82.4%, respectively. Multivariate analysis identified SOFA (Sequential Organ Failure Assessment) score (OR = 1.293, 95% CI [1.113-1.501], p = 0.001), mechanical ventilation (OR = 5.005, 95% CI [1.379-18.157], p = 0.014), and a high Charlson Comorbidity Index (OR = 1.353, 95% CI [1.103-1.650], p = 0.004) as independent predictors of mortality. Combination antibiotic therapy had no significant effect on mortality. No resistance to…
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.